A single mismatched unit or an inconsistent MedDRA Preferred Term can turn an otherwise solid regulatory submission into a linguistic review finding—or worse, a patient safety event. Pharmaceutical labeling and package leaflets sit at the intersection of clinical accuracy, regulatory prescription, and everyday readability. When those documents move across languages, the room for error narrows sharply.
Dosage instructions illustrate the problem most clearly. English “once daily” left untranslated on a Spanish label has been read by patients as “eleven times a day,” because “once” is the Spanish word for eleven. Confusions between mg and µg, mL and L, or the placement of decimal separators (dot versus comma) appear repeatedly in documented incidents. These are not obscure edge cases. Analyses of FDA drug recall data from 2012–2023 attribute roughly 19 percent of recalls to labeling or packaging issues. On the patient side, studies of computer-generated Spanish prescription labels have shown error rates approaching 50 percent in some pharmacy settings.
Contraindications and undesirable effects carry the same risk. Softening an absolute contraindication into a precaution, omitting an interaction, or scattering clinically related reactions across different MedDRA terms dilutes the signal that healthcare professionals and patients need. Section 4.8 of the Summary of Product Characteristics (SmPC) relies on MedDRA terminology precisely because the dictionary’s hierarchical structure and unique numeric codes allow the same clinical concept to map consistently across languages. Using an unofficial synonym, even one that reads more naturally, breaks that mapping and can reclassify severity or obscure pharmacovigilance signals.
The EMA QRD Framework and Why It Leaves Little Room for Paraphrase
In the European Union the Quality Review of Documents (QRD) templates dictate structure, standard headings, and many fixed phrases for the SmPC, package leaflet, and labelling. The templates exist in the official languages of the EU plus Icelandic and Norwegian. Standard statements cannot be reworded; each language version must use the EMA-approved rendering. Deviations identified during linguistic review commonly trigger comments that compress correction windows and risk delaying marketing authorisation.
National “blue box” requirements and Member State preferences add further layers. Decimal formatting, number grouping, and certain abbreviations follow language-specific conventions set out in the QRD style guidance. A translation that ignores those conventions may be linguistically fluent yet non-compliant.
MedDRA sits at the centre of the adverse-reaction sections. Translators and reviewers work from the official MedDRA release relevant to the submission rather than general medical dictionaries. The same eight-digit code links equivalent terms across languages, supporting interoperability between industry and regulators. Recent CIOMS work on MedDRA Labelling Groupings (MLGs) aims to improve clarity by clustering near-synonymous Preferred Terms that convey the same clinical concept, reducing the scatter that high granularity can produce in product labels. Until such groupings are more widely standardised, sponsors and their language partners must still manage consistency product by product and language by language.
Outside the EU the picture changes but the stakes remain high. FDA labelling is primarily English under 21 CFR 201.15, with limited exceptions for territories where another language predominates. Dual-language labelling is permitted, yet any required information appearing in a foreign language must also appear in English. Structured Product Labeling (SPL) and Physician Labeling Rule formats impose their own consistency demands. Errors in unit conversion or contraindication wording still surface in recalls and adverse-event reports.
Practical Controls That Reduce Risk
Teams that treat terminology as a controlled asset rather than a by-product of translation fare better. Product-specific glossaries aligned with the current MedDRA version and the latest QRD decisions, version-controlled translation memories, and dual review by both linguistic and medical specialists form the baseline. Numerical validation—checking every dosage figure, unit, and frequency expression against the source—catches many of the highest-risk errors that pure linguistic review can miss. In-country or affiliate review adds the final filter for national preferences and readability.
Timeline pressure is real. In the centralised procedure, linguistic review comments arrive with short response windows. Late English amendments must propagate correctly to every language version. Change-management protocols that track which source revisions affect which language files prevent the cascade of inconsistencies that reviewers notice immediately.
Cost discussions often focus on per-word rates for multilingual pharmaceutical labeling translation. The more relevant metric is the cost of non-compliance: delayed approvals, resubmissions, product recalls, and potential harm. Quality processes that incorporate MedDRA management and QRD template fidelity reduce those downstream costs more effectively than the cheapest initial quote.
Looking Ahead
QRD templates continue to evolve—version 11 has been under consultation with attention to package-leaflet structure and readability—and MedDRA updates arrive regularly. Sponsors operating in multiple jurisdictions therefore need language partners who maintain current regulatory knowledge rather than treating each project as an isolated linguistic exercise.
Organisations that manage large volumes of product information across dozens of languages benefit from partners with established medical and regulatory translation capability. Artlangs Translation has spent more than twenty years delivering specialised language services, drawing on a network of over 20,000 professional linguists and covering more than 230 languages. The company has supported numerous pharmaceutical and life-science clients with package-insert and labelling work while also maintaining broader expertise in video localisation, short-drama subtitle localisation, game localisation, multilingual dubbing for short-form content and audiobooks, and multilingual data annotation and transcription. That combination of regulatory depth and operational scale allows consistent terminology control and audit-ready documentation across complex, multi-market submissions.
Accurate pharmaceutical labeling translation is not primarily a matter of fluent prose. It is a controlled process that protects patients, satisfies regulators, and keeps products on the market. The difference between a compliant set of language versions and a set that triggers findings often lies in how carefully dosage units, contraindications, and MedDRA terms are managed from the first draft through final linguistic review.
